{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:57:17Z","timestamp":1790758637399,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,4]]},"DOI":"10.7759\/cureus.12482","type":"journal-article","created":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T03:24:14Z","timestamp":1609817054000},"source":"Crossref","is-referenced-by-count":17,"title":["A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases"],"prefix":"10.7759","author":[{"given":"Parth V","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Balani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel R","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea Mae N","family":"Nobleza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariah","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00123","article-title":"Fibroblasts in fibrosis: novel roles and mediators","volume":"5","author":"Kendall RT","year":"2014","unstructured":"Kendall RT, Feghali-Bostwick CA. Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol. 2014, 5:123. 10.3389\/fphar.2014.00123","journal-title":"Front Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn TA","year":"2008","unstructured":"Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008, 214:199-210. 10.1002\/path.2277","journal-title":"J Pathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.11579","article-title":"Role and new insights of pirfenidone in fibrotic diseases","volume":"12","author":"Lopez-de la Mora DA","year":"2015","unstructured":"Lopez-de la Mora DA, Sanchez-Roque C, Montoya-Buelna M, Sanchez-Enriquez S, Lucano-Landeros S, Macias-Barragan J, Armendariz-Borunda J. Role and new insights of pirfenidone in fibrotic diseases. Int J Med Sci. 2015, 12:840-7. 10.7150\/ijms.11579","journal-title":"Int J Med Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.16-1-42","article-title":"Therapeutic advances in idiopathic pulmonary fibrosis","volume":"16","author":"Fraser E","year":"2016","unstructured":"Fraser E, Hoyles RK. Therapeutic advances in idiopathic pulmonary fibrosis. Clin Med (Lond). 2016, 16:42-51. 10.7861\/clinmedicine.16-1-42","journal-title":"Clin Med (Lond)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2014.02.014","article-title":"Effect of pirfenidone on proliferation, TGF-\u03b2-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts","volume":"58","author":"Conte E","year":"2014","unstructured":"Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. Effect of pirfenidone on proliferation, TGF-\u03b2-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014, 58:13-19. 10.1016\/j.ejps.2014.02.014","journal-title":"Eur J Pharm Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010101049","article-title":"Pirfenidone for diabetic nephropathy","volume":"22","author":"Sharma K","year":"2011","unstructured":"Sharma K, Ix JH, Mathew AV, et al.. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol. 2011, 22:1144-1151. 10.1681\/ASN.2010101049","journal-title":"J Am Soc Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2011.139","article-title":"The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice","volume":"35","author":"Yamazaki T","year":"2012","unstructured":"Yamazaki T, Yamashita N, Izumi Y, et al.. The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice. Hypertens Res. 2012, 35:34-40. 10.1038\/hr.2011.139","journal-title":"Hypertens Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4257","article-title":"Antifibrotic effect of pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels","volume":"51","author":"Kim H","year":"2010","unstructured":"Kim H, Choi YH, Park SJ, Lee SY, Kim SJ, Jou I, Kook KH. Antifibrotic effect of pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels. Invest Ophthalmol Vis Sci. 2010, 51:3061-3066. 10.1167\/iovs.09-4257","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-14-131","article-title":"Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C","volume":"14","author":"Flores-Contreras L","year":"2014","unstructured":"Flores-Contreras L, Sandoval-Rodr\u00edguez AS, Mena-Enriquez MG, et al.. Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C. BMC Gastroenterol. 2014, 14:131. 10.1186\/1471-230X-14-131","journal-title":"BMC Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13247","article-title":"Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease","volume":"21","author":"Xiao H","year":"2018","unstructured":"Xiao H, Zhang GF, Liao XP, et al.. Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease. Int J Rheum Dis. 2018, 21:477-486. 10.1111\/1756-185X.13247","journal-title":"Int J Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1093-z","article-title":"Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-\u03b21","volume":"20","author":"Jin J","year":"2019","unstructured":"Jin J, Togo S, Kadoya K, et al.. Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-\u03b21. Respir Res. 2019, 20:119. 10.1186\/s12931-019-1093-z","journal-title":"Respir Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201701-0091OC","article-title":"Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis","volume":"196","author":"Ley B","year":"2017","unstructured":"Ley B, Swigris J, Day BM, Stauffer JL, Raimundo K, Chou W, Collard HR. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017, 196:756-761. 10.1164\/rccm.201701-0091OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1565530","article-title":"Pirfenidone improves the survival of patients with idiopathic pulmonary fibrosis hospitalized for acute exacerbation","volume":"35","author":"Vianello A","year":"2019","unstructured":"Vianello A, Molena B, Turato C, et al.. Pirfenidone improves the survival of patients with idiopathic pulmonary fibrosis hospitalized for acute exacerbation. Curr Med Res Opin. 2019, 35:1187-1190. 10.1080\/03007995.2019.1565530","journal-title":"Curr Med Res Opin"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.11.008","article-title":"Efficacy of pirfenidone in the context of multiple disease progression events in patients with idiopathic pulmonary fibrosis","volume":"155","author":"Nathan SD","year":"2019","unstructured":"Nathan SD, Costabel U, Glaspole I, et al.. Efficacy of pirfenidone in the context of multiple disease progression events in patients with idiopathic pulmonary fibrosis. Chest. 2019, 155:712-719. 10.1016\/j.chest.2018.11.008","journal-title":"Chest"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.04.016","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment","volume":"153","author":"Nathan SD","year":"2019","unstructured":"Nathan SD, Costabel U, Albera C, et al.. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respir Med. 2019, 153:44-51. 10.1016\/j.rmed.2019.04.016","journal-title":"Respir Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000479976","article-title":"An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP)","volume":"94","author":"Costabel U","year":"2017","unstructured":"Costabel U, Albera C, Lancaster LH, Lin CY, Hormel P, Hulter HN, Noble PW. An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP). Respiration. 2017, 94:408-415. 10.1159\/000479976","journal-title":"Respiration"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-018-0736-z","article-title":"Pirfenidone improves survival in IPF: results from a real-life study","volume":"18","author":"Margaritopoulos GA","year":"2018","unstructured":"Margaritopoulos GA, Trachalaki A, Wells AU, et al.. Pirfenidone improves survival in IPF: results from a real-life study. BMC Pulm Med. 2018, 18:177. 10.1186\/s12890-018-0736-z","journal-title":"BMC Pulm Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1021-2","article-title":"Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis","volume":"20","author":"Costabel U","year":"2019","unstructured":"Costabel U, Albera C, Glassberg MK, et al.. Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. Respir Res. 2019, 20:55-10. 10.1186\/s12931-019-1021-2","journal-title":"Respir Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28297-x","article-title":"Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo","volume":"8","author":"Li C","year":"2018","unstructured":"Li C, Rezov V, Joensuu E, et al.. Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo. Sci Rep. 2018, 8:10070. 10.1038\/s41598-018-28297-x","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-016-1326-y","article-title":"Anti-fibrotic action of pirfenidone in Dupuytren's disease-derived fibroblasts","volume":"17","author":"Zhou C","year":"2016","unstructured":"Zhou C, Liu F, Gallo PH, Baratz ME, Kathju S, Satish L. Anti-fibrotic action of pirfenidone in Dupuytren's disease-derived fibroblasts. BMC Musculoskelet Disord. 2016, 17:469. 10.1186\/s12891-016-1326-y","journal-title":"BMC Musculoskelet Disord"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2018.05.003","article-title":"Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation","volume":"99","author":"Li Y","year":"2018","unstructured":"Li Y, Li H, Liu S, et al.. Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation. Mol Immunol. 2018, 99:134-144. 10.1016\/j.molimm.2018.05.003","journal-title":"Mol Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-019-0255-4","article-title":"Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages","volume":"99","author":"Chen G","year":"2019","unstructured":"Chen G, Ni Y, Nagata N, et al.. Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages. Lab Invest. 2019, 99:1335-1348. 10.1038\/s41374-019-0255-4","journal-title":"Lab Invest"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2019.04.005","article-title":"Protective role of pirfenidone against experimentally-induced pancreatitis","volume":"71","author":"El-Kashef DH","year":"2019","unstructured":"El-Kashef DH, Shaaban AA, El-Agamy DS. Protective role of pirfenidone against experimentally-induced pancreatitis. Pharmacol Rep. 2019, 71:774-781. 10.1016\/j.pharep.2019.04.005","journal-title":"Pharmacol Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial","volume":"43","author":"Khanna D","year":"2016","unstructured":"Khanna D, Albera C, Fischer A, et al.. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol. 2016, 43:1672-9. 10.3899\/jrheum.151322","journal-title":"J Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13247","article-title":"Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease","volume":"21","author":"Xiao H","year":"2018","unstructured":"Xiao H, Zhang GF, Liao XP, et al.. Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease. Int J Rheum Dis. 2018, 21:477-486. 10.1111\/1756-185X.13247","journal-title":"Int J Rheum Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.36141\/svdld.v35i2.6170","article-title":"Pirfenidone in chronic hypersensitivity pneumonitis: a real-life experience","volume":"35","author":"Shibata S","year":"2018","unstructured":"Shibata S, Furusawa H, Inase N. Pirfenidone in chronic hypersensitivity pneumonitis: a real-life experience. Sarcoidosis Vasc Diffuse Lung Dis. 2018, 35:139-142. 10.36141\/svdld.v35i2.6170","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2019.10.177","article-title":"Pirfenidone attenuates the pro-fibrotic contractile phenotype of differentiated human dermal myofibroblasts","volume":"521","author":"Wells AR","year":"2020","unstructured":"Wells AR, Leung KP. Pirfenidone attenuates the pro-fibrotic contractile phenotype of differentiated human dermal myofibroblasts. Biochem Biophys Res Commun. 2020, 521:646-651. 10.1016\/j.bbrc.2019.10.177","journal-title":"Biochem Biophys Res Commun"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0007","article-title":"The antiangiogenesis effect of pirfenidone in wound healing in vitro","volume":"33","author":"Liu X","year":"2017","unstructured":"Liu X, Yang Y, Guo X, Liu L, Wu K, Yu M. The antiangiogenesis effect of pirfenidone in wound healing in vitro. J Ocul Pharmacol Ther. 2017, 33:693-703. 10.1089\/jop.2017.0007","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-018-0541-5","article-title":"Controlled delivery of pirfenidone through vitamin E-loaded contact lens ameliorates corneal inflammation","volume":"8","author":"Dixon P","year":"2018","unstructured":"Dixon P, Ghosh T, Mondal K, Konar A, Chauhan A, Hazra S. Controlled delivery of pirfenidone through vitamin E-loaded contact lens ameliorates corneal inflammation. Drug Deliv Transl Res. 2018, 8:1114-1126. 10.1007\/s13346-018-0541-5","journal-title":"Drug Deliv Transl Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.21","article-title":"Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy","volume":"31","author":"Khanum BK","year":"2017","unstructured":"Khanum BK, Guha R, Sur VP, Nandi S, Basak SK, Konar A, Hazra S. Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy. Eye (Lond). 2017, 31:1317-1328. 10.1038\/eye.2017.21","journal-title":"Eye (Lond)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181ae3392","article-title":"Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses","volume":"88","author":"Visner GA","year":"2009","unstructured":"Visner GA, Liu F, Bizargity P, et al.. Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses. Transplantation. 2009, 88:330-8. 10.1097\/TP.0b013e3181ae3392","journal-title":"Transplantation"},{"key":"ref32","article-title":"Pirfenidone in restrictive allograft syndrome after lung transplantation: a case series","volume":"18","author":"Vos R","year":"2018","unstructured":"Vos R, Wuyts WA, Gheysens O, et al.. Pirfenidone in restrictive allograft syndrome after lung transplantation: a case series. Am J Transplant. 2018, 18:3045-3059.","journal-title":"Am J Transplant"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/45106-a-review-of-pirfenidone-as-an-anti-fibrotic-in-idiopathic-pulmonary-fibrosis-and-its-probable-role-in-other-diseases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:27:30Z","timestamp":1707506850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/45106-a-review-of-pirfenidone-as-an-anti-fibrotic-in-idiopathic-pulmonary-fibrosis-and-its-probable-role-in-other-diseases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.12482","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,4]]}}}